LinusBio Raises $16 Million to Scale Growth and Deliver Tangible Outcomes
LinusBio, a leader in precision exposome sequencing, today announced it raised over $16 million in Series A funding to deliver a novel platform that bridges genomics, the environment, and biological response.
Keep readingNovozymes and LinusBio announce collaboration to accelerate scientific discovery in Biohealth
Novozymes and LinusBio announced the companies are forming a collaboration to test a new, non-invasive technology in a clinical trial.
Keep readingLinusBio Recognized at the 2022 Mount Sinai Innovation Awards
The biotech startup, that developed a novel precision exposome sequencing platform, has been selected as the winner of the Transaction of the Year award On Monday October 24 2022, the Icahn School of Medicine at Mount Sinai hosted the 8th annual Mount Sinai Innovation Awards, celebrating numerous honors that recognize significant contributions in biomedical education and industry. Drs. Manish Arora, Christine Austin and Paul Curtin – co-founders of LinusBio – were presented…
Keep readingWATCH: Detecting Autism at Birth and Opportunity for Early Intervention
Detecting autism at Birth and Opportunity for Early Intervention: Manish Arora, PhD, Founder, CEO and CSO at Linus Bio, speaks at the Institute for Exposomic Research at Mount Sinai.
Keep readingWATCH: HITLAB 2021 Innovator’s Summit Presentation
Manish Arora, PHD, Co-Founder of Linus Biotechnology speaks at HITLAB 2021 Innovator’s Summit Presentation
Keep readingLinus Biotechnology Inc. Receives FDA Breakthrough Device Designation for StrandDx™-ASD Exposome Sequencing Diagnostic
Linus Biotechnology Inc., a leader in precision exposome sequencing, today announced that the U.S. Food and Drug Administration Center for Devices and Radiological Health has granted the Company’s StrandDx™-ASD diagnostic aid the designation as a Breakthrough Device for Autism Spectrum Disorder (ASD)
Keep readingMount Sinai Spin-Off Linus Biotechnology Inc. to Revolutionize Precision Medicine with Exposome Sequencing
LinusBio is a novel biotechnology company dedicated to developing and commercializing molecular exposome and biological-response sequencing for complex diseases for which genomic sequencing alone cannot sufficiently characterize underlying biological disease pathways
Keep readingFor Media Inquires
Press@linusbio.com
